Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Phone608-284-5700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$454.46 million
Profitability
Miscellaneous
Employees1,977
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions
What is EXACT Sciences' stock symbol?
EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."
How were EXACT Sciences' earnings last quarter?
EXACT Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings results on Tuesday, April, 30th. The medical research company reported ($0.66) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.65) by $0.01. The medical research company earned $162 million during the quarter, compared to analyst estimates of $153.07 million. EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The company's quarterly revenue was up 79.4% on a year-over-year basis. During the same period last year, the firm posted ($0.33) earnings per share. View EXACT Sciences' Earnings History.
When is EXACT Sciences' next earnings date?
What guidance has EXACT Sciences issued on next quarter's earnings?
EXACT Sciences issued an update on its FY 2019 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $725-740 million, compared to the consensus revenue estimate of $729.45 million.
What price target have analysts set for EXAS?
12 brokers have issued 12-month price objectives for EXACT Sciences' stock. Their predictions range from $90.00 to $130.00. On average, they anticipate EXACT Sciences' share price to reach $109.40 in the next year. This suggests that the stock has a possible downside of 5.4%. View Analyst Price Targets for EXACT Sciences.
What is the consensus analysts' recommendation for EXACT Sciences?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.
Has EXACT Sciences been receiving favorable news coverage?
News headlines about EXAS stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. EXACT Sciences earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the company's share price in the near term. View News Stories for EXACT Sciences.
Who are some of EXACT Sciences' key competitors?
Some companies that are related to EXACT Sciences include Iqvia (IQV), Incyte (INCY), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).
What other stocks do shareholders of EXACT Sciences own?
Who are EXACT Sciences' key executives?
EXACT Sciences' management team includes the folowing people:
- Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
- Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)
- Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
- Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Mark Stenhouse, Pres of Cologuard (Age 52)
Who are EXACT Sciences' major shareholders?
EXACT Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (2.31%), OppenheimerFunds Inc. (1.94%), Gilder Gagnon Howe & Co. LLC (1.55%), Zevenbergen Capital Investments LLC (1.43%), Artisan Partners Limited Partnership (1.40%) and William Blair Investment Management LLC (1.10%). Company insiders that own EXACT Sciences stock include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.
Which major investors are selling EXACT Sciences stock?
EXAS stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, William Blair Investment Management LLC, BNP Paribas Arbitrage SA, OppenheimerFunds Inc., Zevenbergen Capital Investments LLC, First Trust Advisors LP, Frontier Capital Management Co. LLC and Primecap Management Co. CA. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.
Which major investors are buying EXACT Sciences stock?
EXAS stock was acquired by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Kornitzer Capital Management Inc. KS, CIBC Private Wealth Group LLC, Spark Investment Management LLC, Gilder Gagnon Howe & Co. LLC, Eagle Asset Management Inc., Rhenman & Partners Asset Management AB and Strs Ohio. View Insider Buying and Selling for EXACT Sciences.
How do I buy shares of EXACT Sciences?
Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EXACT Sciences' stock price today?
One share of EXAS stock can currently be purchased for approximately $115.70.
How big of a company is EXACT Sciences?
EXACT Sciences has a market capitalization of $14.94 billion and generates $454.46 million in revenue each year. The medical research company earns $-175,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.View Additional Information About EXACT Sciences.
What is EXACT Sciences' official website?
How can I contact EXACT Sciences?
EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.
MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
